Role and application prospect of growth stimulation expressed gene 2 factor in diagnosis and prognosis of cardiovascular events in patients with coronavirus disease 2019
Received:February 28, 2020  
View Full Text  View/Add Comment  Download reader
Key words:coronavirus disease 2019  growth stimulation expressed gene 2  myocardial damage  acute heart failure  marker Corresponding author:CHEN Yun-Dai,〖FL
Author NameAffiliationE-mail
ZHANG Xian-Wei Department of Health Service, Guard Bureau of the Joint Staff, Beijing 100017, China cyundai@vip.163.comrole 
CHEN Yun-Dai Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China cyundai@vip.163.comrole 
Hits: 857
Download times: 663
      Since the outbreak of coronavirus disease 2019(COVID-19)in Wuhan, the epidemic subsequently reached other provinces in China. From the clinical treatment of critical patients, evidence shows that the elderly patients with cardiovascular diseases, diabetes and other underlying medical conditions have higher risk of death. Meanwhile, COVID-19 patients were found to be bearing myocardial damage, heart failure and other cardiovascular function impairment. It is quite urgent for us to identify the indicators and detection methods of myocardial injury as soon as possible, which is of great importance to improve the success rate of rescuing critical patients with COVID-19. Growth stimulation expressed gene 2 (ST2), a plasma protein, is confirmed to act as a decoy receptor for interleukin-33. Based on its unique signal transduction pathway and pathophysiological mechanism, ST2, a novel cardiac marker for heart failure and myocardial injury, is expected to be combined with B-type natriuretic peptide (BNP) and other indicators to provide a reference of diagnosis and treatment for heart failure and myocardial damage in COVID-19 patients.